ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,651 | -80.4% | 1,043 | -62.4% | 0.00% | – |
| Q2 2023 | $59,299 | +30.6% | 2,771 | +146.7% | 0.00% | – |
| Q1 2023 | $45,414 | -7.3% | 1,123 | +6.6% | 0.00% | – |
| Q4 2022 | $48,986 | -10.9% | 1,053 | -0.4% | 0.00% | – |
| Q3 2022 | $55,000 | +120.0% | 1,057 | +102.1% | 0.00% | – |
| Q2 2022 | $25,000 | -68.8% | 523 | -54.1% | 0.00% | – |
| Q1 2022 | $80,000 | -4.8% | 1,140 | +2.4% | 0.00% | – |
| Q4 2021 | $84,000 | +52.7% | 1,113 | +15.9% | 0.00% | – |
| Q3 2021 | $55,000 | -21.4% | 960 | -40.0% | 0.00% | – |
| Q2 2021 | $70,000 | +79.5% | 1,601 | +103.4% | 0.00% | – |
| Q1 2021 | $39,000 | +69.6% | 787 | +42.8% | 0.00% | – |
| Q4 2020 | $23,000 | -53.1% | 551 | -49.2% | 0.00% | – |
| Q3 2020 | $49,000 | -9.3% | 1,084 | +1.2% | 0.00% | – |
| Q2 2020 | $54,000 | -3.6% | 1,071 | +0.3% | 0.00% | – |
| Q1 2020 | $56,000 | +19.1% | 1,068 | +39.2% | 0.00% | – |
| Q4 2019 | $47,000 | +6.8% | 767 | +3.2% | 0.00% | – |
| Q3 2019 | $44,000 | -32.3% | 743 | -4.3% | 0.00% | – |
| Q2 2019 | $65,000 | -8.5% | 776 | +4.6% | 0.00% | – |
| Q1 2019 | $71,000 | +57.8% | 742 | +17.0% | 0.00% | – |
| Q4 2018 | $45,000 | +36.4% | 634 | +64.7% | 0.00% | – |
| Q3 2018 | $33,000 | -23.3% | 385 | +4.1% | 0.00% | – |
| Q2 2018 | $43,000 | +95.5% | 370 | +39.1% | 0.00% | – |
| Q1 2018 | $22,000 | +120.0% | 266 | +59.3% | 0.00% | – |
| Q4 2017 | $10,000 | +25.0% | 167 | -1.8% | 0.00% | – |
| Q3 2017 | $8,000 | -99.7% | 170 | -99.8% | 0.00% | -100.0% |
| Q2 2017 | $2,472,000 | +16.4% | 68,703 | -0.3% | 0.00% | +50.0% |
| Q1 2017 | $2,123,000 | -24.8% | 68,915 | -18.2% | 0.00% | -33.3% |
| Q4 2016 | $2,823,000 | +622.0% | 84,236 | +473.3% | 0.00% | – |
| Q3 2016 | $391,000 | +26.1% | 14,692 | +4.6% | 0.00% | – |
| Q2 2016 | $310,000 | +17.9% | 14,042 | +57.1% | 0.00% | – |
| Q1 2016 | $263,000 | +11.0% | 8,939 | +25.1% | 0.00% | – |
| Q4 2015 | $237,000 | -50.3% | 7,143 | -45.8% | 0.00% | -100.0% |
| Q3 2015 | $477,000 | -19.7% | 13,181 | -0.4% | 0.00% | 0.0% |
| Q2 2015 | $594,000 | +14750.0% | 13,231 | +9217.6% | 0.00% | – |
| Q1 2015 | $4,000 | -98.7% | 142 | -97.6% | 0.00% | – |
| Q4 2014 | $303,000 | +78.2% | 5,959 | +38.6% | 0.00% | – |
| Q3 2014 | $170,000 | -41.4% | 4,300 | -36.0% | 0.00% | – |
| Q2 2014 | $290,000 | +3.6% | 6,723 | -3.9% | 0.00% | – |
| Q1 2014 | $280,000 | – | 6,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |